Trials / Completed
CompletedNCT03516123
A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors
A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, PK and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- CStone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open label, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS3006 | In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, participants will receive CS3006 at specified dose level(s). |
Timeline
- Start date
- 2018-06-14
- Primary completion
- 2020-06-18
- Completion
- 2020-06-18
- First posted
- 2018-05-04
- Last updated
- 2024-09-19
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT03516123. Inclusion in this directory is not an endorsement.